Fig. 1.

The CI values were determined for the combination treatment of propofol with cisplatin or doxorubicin in human ovarian cancer cells. (A and B) SKOV3 cells were treated with 0, 0.625, 1.25, 2.5, 5, 10, 20, 40, 80, and 160 µg/ml propofol combined with (A) 0, 1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 µM cisplatin or (B) 0, 0.625, 1.25, 2.5, 5, 10, 20, and 40 µM doxorubicin for 24 h. (C and D) OVCAR3 cells were treated with 0, 0.390625, 0.78125, 1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 µg/ml propofol combined with (C) 0, 1.25, 2.5, 5, 10, 20, 40, and 80 µM cisplatin or (D) 0, 0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, and 5 µM doxorubicin for 24 h. Cell viability was measured according to the MTT method. The experimental points below the line correspond to CI < 1, indicating a synergistic effect